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Abstract 
Following an application from Beghin-Meiji and Tereos Syral, submitted for authorisation of a health 
claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of 
France, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA Panel) was asked to deliver 
an opinion on the scientific substantiation of a health claim related to short-chain 
fructooligosaccharides (scFOS) from sucrose and maintenance of normal defecation. The food 
constituent that is the subject of the health claim is scFOS from sucrose. The Panel considers that 
scFOS from sucrose is sufficiently characterised. The claimed effect proposed by the applicant is 
‘maintaining normal intestinal transit regularity by increasing stool frequency’. The target population 
proposed by the applicant is the general population. Upon a request from EFSA, the applicant 
confirmed that the proposed claimed effect refers to maintenance of normal defecation. The Panel 
considers that maintenance of normal defecation is a beneficial physiological effect. The Panel 
considers that one human intervention study did not show an effect of scFOS from sucrose at a dose 
of 5.7 g/day for 4 weeks on defecation frequency, consistency of stools or dry faecal mass and that in 
two other human intervention studies 10 g/day of scFOS increased faecal bulk, whereas higher 
amounts (12.5 g/day) consumed for shorter period did not. Although a number of studies provided 
some evidence that scFOS are fermented in the colon and increase bacterial mass and faecal bulk, the 
information provided does not demonstrate that the changes in short-chain fatty acids (SCFA) or bile 
acids induced by scFOS lead to significant changes in the frequency of stools. The Panel concludes 
that a cause and effect relationship has not been established between the consumption of scFOS from 
sucrose and maintenance of normal defecation under proposed conditions of use. 
© European Food Safety Authority, 2016 
 
Keywords: short-chain fructooligosaccharides from sucrose, defecation, bowel function, constipation, 
health claim  
 
Requestor: Competent Authority of France following an application by Beghin-Meiji and Tereos Syral. 
Question number: EFSA-Q-2015-00377 
Correspondence: nda@efsa.europa.eu  
 
Short-chain FOS from sucrose and normal defecation 
 
 
 
www.efsa.europa.eu/efsajournal 2 EFSA Journal 2016;14(1):4366 
 
 
Panel members: Jean Louis Bresson, Barbara Burlingame, Tara Dean, Susan Fairweather-Tait, 
Marina Heinonen, Karen Ildico Hirsch-Ernst, Inge Mangelsdorf, Harry McArdle, Androniki Naska, 
Monika Neuhäuser-Berthold, Grażyna Nowicka, Kristina Pentieva, Yolanda Sanz, Alfonso Siani, Anders 
Sjödin, Martin Stern, Daniel Tomé, Dominique Turck, Hendrik Van Loveren, Marco Vinceti and Peter 
Willatts. 
Acknowledgements: The Panel wishes to thank the members of the Working Group on Claims: 
Jean-Louis Bresson, Susan Fairweather-Tait, Marina Heinonen, Ambroise Martin, Harry McArdle, 
Yolanda Sanz, Alfonso Siani, Anders Sjödin, Sean (JJ) Strain, Hendrik Van Loveren and Peter Willatts 
for the preparatory work on this scientific output.  
Suggested citation: EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies), 
2016. Scientific opinion on short-chain fructooligosaccharides from sucrose and maintenance of 
normal defecation: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) 
No 1924/2006. EFSA Journal 2016;14(1):4366, 14 pp. doi:10.2903/j.efsa.2016.4366 
ISSN: 1831-4732 
© European Food Safety Authority, 2016 
Reproduction is authorised provided the source is acknowledged. 
 
 
The EFSA Journal is a publication of the European Food 
 Safety Authority, an agency of the European Union. 
 
 
 
Short-chain FOS from sucrose and normal defecation 
 
 
 
www.efsa.europa.eu/efsajournal 3 EFSA Journal 2016;14(1):4366 
 
 
Summary 
Following an application from Beghin-Meiji and Tereos Syral submitted for authorisation of a health 
claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of 
France, the European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies 
(NDA Panel) was asked to deliver an opinion on the scientific substantiation of a health claim related 
to short-chain fructooligosaccharides (scFOS) from sucrose and maintenance of normal defecation. 
The scope of the application was proposed to fall under a health claim based on newly developed 
scientific evidence. The application included a request for the protection of proprietary data. 
The general approach of the NDA Panel for the evaluation of health claim applications is outlined in 
the EFSA general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health 
claims. 
The food constituent that is the subject of the health claim is short-chain fructooligosaccharides from 
sucrose. The Panel considers that the food constituent, scFOS from sucrose, is sufficiently 
characterised. 
The claimed effect proposed by the applicant is ‘maintaining normal intestinal transit regularity by 
increasing stool frequency’. The target population proposed by the applicant is ‘general population’. 
Upon a request from EFSA, the applicant confirmed that the proposed claimed effect refers to 
maintenance of normal defecation. 
The Panel considers that maintenance of normal defecation is a beneficial physiological effect. 
A total of 17 human studies, 11 animal studies and 6 in vitro studies have been identified by the 
applicant as being pertinent to the health claim. 
In weighing the evidence, the Panel took into account that one human intervention study from which 
conclusions could be drawn did not show an effect of scFOS from sucrose consumed at a dose of 
5.7 g/day for 4 weeks on defecation frequency, consistency of stools or dry faecal mass, and that in 
two other human intervention studies 10 g/day of scFOS consumed for 5 weeks increased faecal bulk, 
whereas higher amounts (12.5 g/day) consumed for shorter period of time (12 days) did not. The 
Panel also took into account that, although a number of animal efficacy studies and mechanistic 
studies provided some evidence that scFOS are fermented in the colon by the gut microbiota and 
increase bacterial mass and faecal bulk, the information provided by those studies does not 
demonstrate that the changes in short-chain fatty acids (SCFA) or bile acids which may be induced by 
scFOS lead to significant changes in the frequency of stools. 
On the basis of data presented, the Panel concludes that a cause and effect relationship has not been 
established between the consumption of scFOS from sucrose and maintenance of normal defecation 
under proposed conditions of use. 
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1. Introduction  
1.1. Background and Terms of Reference as provided by the requestor 
Regulation (EC) No 1924/20061 harmonises the provisions that relate to nutrition and health claims, 
and establishes rules governing the Community authorisation of health claims made on foods. As a 
rule, health claims are prohibited unless they comply with the general and specific requirements of 
this Regulation, are authorised in accordance with this Regulation and are included in the lists of 
authorised claims provided for in Articles 13 and 14 thereof. In particular, Article 13(5) of this 
Regulation lays down provisions for the addition of claims (other than those referring to the reduction 
in disease risk and to children’s development and health) which are based on newly developed 
scientific evidence, or which include a request for the protection of proprietary data, to the 
Community list of permitted claims referred to in Article 13(3). 
According to Article 18 of this Regulation, an application for inclusion in the Community list of 
permitted claims referred to in Article 13(3) shall be submitted by the applicant to the national 
competent authority of a Member State, which will make the application and any supplementary 
information supplied by the applicant available to the European Food Safety Authority (EFSA). 
1.2. Interpretation of the Terms of Reference 
EFSA is requested to evaluate the scientific data submitted by the applicant in accordance with Article 
16(3) of Regulation (EC) No 1924/2006. On the basis of that evaluation, EFSA will issue an opinion on 
the scientific substantiation of a health claim related to: short-chain fructooligosaccharides (scFOS) 
from sucrose and maintenance of normal defecation. 
The present opinion does not constitute, and cannot be construed as, an authorisation for the 
marketing of scFOS from sucrose, a positive assessment of its safety, nor a decision on whether 
scFOS from sucrose is, or is not, classified as a foodstuff. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wording of the claim, and the conditions of 
use as proposed by the applicant may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 18(4) of Regulation (EC) No 1924/2006. 
1.3. Additional information 
A claim on fructooligosaccharides from sucrose and changes in bowel function has already been 
assessed by the Panel with unfavourable outcome (EFSA NDA Panel, 2011a). 
2. Data and Methodologies  
2.1.1. Data 
2.1.2. Information provided by the applicant 
Food constituent as stated by the applicant 
According to the applicant, the food that is the subject of the claim is scFOS obtained from sucrose 
being the combination of 1-kestose (glucose–fructose–fructose (GF2)) (37 ± 6%), nystose (glucose–
fructose–fructose–fructose (GF3)) (53 ± 6%) and 1F-β-fructofuranosyl nystose (glucose–fructose–
fructose–fructose–fructose (GF4)) (10 ± 6%). GF2, GF3 and GF4 are formed by a sucrose (glucose–
fructose) molecule linked to, respectively, one, two or three fructose units by  2-1 glycosidic bounds 
to the fructose unit of sucrose. 
                                                          
1 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health 
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
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Health relationship as claimed by the applicant 
According to the applicant, the claimed effect concerns maintaining normal intestinal transit regularity 
by increasing stool frequency. 
The outcome measure used to assess the health effect on humans with no known structural 
abnormalities or infections or metabolic causes is the change in stool number between the end of 
consumption of scFOS from sucrose and baseline, compared to the consumption of a placebo product. 
Wording of the health claim as proposed by the applicant 
The applicant has proposed the following wording for the health claim: ‘maintain normal intestinal 
regularity’ or ‘maintain intestinal regularity by increasing the frequency of bowel movements’ or 
‘contributes to normal intestinal regularity or normal bowel function’. 
Specific conditions of use as proposed by the applicant 
The applicant has proposed an intake of 4.6 g of dry matter (DM) of the constituent scFOS from 
sucrose per day. The target population proposed by the applicant is the general population. 
Data provided by the applicant 
The applicant provided a health claim application on scFOS from sucrose and maintenance of normal 
defecations pursuant to Article 13.5 of Regulation 1924/2006. The application was presented in a 
common and structured format as outlined in the Scientific and technical guidance for the preparation 
and presentation of applications for authorisation of health claims (EFSA NDA Panel, 2011b). 
As outlined in the EFSA General guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 
14 health claims (EFSA NDA Panel, 2011c), it is the responsibility of the applicant to provide the 
totality of the available evidence. 
2.1.3. Methodologies 
The general approach of the NDA Panel for the evaluation of health claims applications is outlined in 
the EFSA general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health 
claims (EFSA NDA Panel, 2011c). 
The scientific requirements for health claims related to gut and immune function are outlined in a 
specific EFSA guidance (EFSA NDA Panel, 2011d). 
3. Assessment 
3.1. Characterisation of the food constituent 
The food which is the subject of the health claim is ‘scFOS obtained from sucrose’. 
Fructooligosaccharides (FOS) obtained from sucrose are prepared by enzymatic elongation of sucrose 
and consist of a mixture of kestose (GF2), nystose (GF3) and fructosylnystose (GF4), with an average 
degree of polymerisation (DPav) of 3.6, and are sometimes referred to as scFOS. They differ from 
natural fructans by degree of polymerisation (DP) (only 10% of native chicory inulins have a DP 
between 2 and 5 (Roberfroid, 2007) and from oligofructoses prepared by inulin hydrolysis (DP from 2 
to 7, DPav 4) by the systematic presence of a glucose moiety. 
ScFOS are offered as a powder and in liquid forms. Information about manufacturing process, stability 
and variability between batches was provided in the application. ScFOS can be measured in foods by 
established methods. 
The Panel considers that the claim applies to scFOS from sucrose consisting of the combination of 
1-kestose (GF2) (37 ± 6%), nystose (GF3) (53 ± 6%) and 1F-β-fructofuranosyl nystose (GF4) 
(10 ± 6%). 
The Panel considers that the food constituent, scFOS from sucrose, is sufficiently characterised. 
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3.2. Relevance of the claimed effect to human health 
The claimed effect proposed by the applicant is ‘maintaining normal intestinal transit regularity by 
increasing stool frequency’. The target population proposed by the applicant is ‘general population’. 
Upon a request from EFSA, the applicant confirmed that the proposed claimed effect refers to 
maintenance of normal defecation. 
Maintenance of normal defecation may be assessed by a number of outcome variables which could 
provide information about the function and eventually about the underlying mechanism of action, 
some of which may be inter-related (e.g. frequency of defecations, stool consistency, sensation of 
complete/incomplete evacuation, faecal bulk, transit time). Although reduced stool frequency and 
consistency are among the signs/symptoms of functional constipation, changes in transit time and 
faecal bulk may or may not contribute to the maintenance of normal defecation in the context of 
constipation. 
The Panel considers that maintenance of normal defecation is a beneficial physiological effect. 
3.3. Scientific substantiation of the claimed effect 
The applicant performed a literature search in PubMed database and Journal@rchive database with 
the use of the following key words: ("fructooligosaccharide(s)" OR "fructo-oligosaccharide(s)" OR 
“neosugar” OR “actilight” OR “nutraflora” OR “scFOS” AND  ("stool frequency" OR "stool consistency" 
OR "soft stool" OR “stool weight" OR "stool bulk" OR " stool regularity" OR "f(a)ecal weight" OR 
"f(a)ecal mass" OR "f(a)ecal bulk" OR “ f(a)ecal excretion" OR "bowel function" OR "bowel habit(s)" 
OR "bowel regularity" OR "bowel motor function(s)" OR "bowel movement(s)" OR "transit" OR 
"constipation" OR "def(a)ecation" OR “gut function" OR "colonic motility". 
A total of 17 human studies, 11 animal studies and 6 in vitro studies have been identified by the 
applicant as being pertinent to the health claim. 
3.3.1. Efficacy studies 
Efficacy studies in humans 
Ten human intervention studies in adult subjects which investigated the effect of scFOS from sucrose 
on one or more outcomes related to defecation were submitted for the substantiation of the claim. 
The Panel notes that three of the human intervention studies provided (Kameoka et al., 1986; 
Tokunaga et al., 1993; Bouhnik et al., 2007) were one-arm, open-label studies. The Panel also notes 
that another human intervention study investigated the effect of scFOS from sucrose given once only 
(Respondek et al. 2014). The Panel considers that no conclusions can be drawn from these studies for 
the scientific substantiation of the claim. 
Tominaga et al. (1999) studied the effect of scFOS from sucrose (3 g/day given for 2 weeks) vs 
placebo (sucrose) in healthy female volunteers (n = 34, mean age 20 years) in a single-blind, 
placebo-controlled, sequential (2 weeks scFOS from sucrose, 2 weeks wash-out period, 2 weeks 
placebo period) study. The results were presented separately for three groups of subjects according 
to their defecation frequency before the intervention: ‘normal’ (> 5 defecations/week, n = 12), ‘lower’ 
(> 3, and ≤ 5 defecations/week, n = 9) and ‘lowest’ (≤ 3 defecations/week, n = 13). The Panel notes 
that no a priori stratification for subgroup analysis was reported, and that the overall results for the 
intervention with respect to defecation frequency were not provided. The Panel considers that no 
conclusions can be drawn from this study for the scientific evaluation of the claim. 
Bouhnik et al. (2004) investigated the effect of different doses of scFOS from sucrose (2.5, 5, 7.5 and 
10 g/day) given for 7 days to healthy volunteers on Bifidobacteria counts in faeces compared to 
placebo (50% sucrose and 50% maltodextrin). Frequency of defecations was a secondary outcome, 
but the results of the study for this variable were not reported in the publication. The Panel considers 
that no conclusions can be drawn from this study for the scientific evaluation of the claim. 
In a randomised four-arm, double-blind, placebo-controlled, parallel study conducted on healthy 
subjects (n = 68, 42 women, mean age 25 years) with normal frequency of defecations (1.4 bowel 
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movements per day on average), Swanson et al. (2002a) investigated the effect of sucrose, scFOS 
from sucrose, sucrose + Lactobacillus acidophilus, and scFOS from sucrose + Lactobacillus acidophilus 
consumed at doses of 5.7 g/day for 4 weeks on several aspects of intestinal function, including 
frequency of defecations, stool consistency, faecal dry mass and the chemical content of faeces. 
Subjects recorded frequency of defecations and stool consistency (assessed with a 5-point scale) in a 
diary. Fresh faecal samples were collected 3 times during the study: at the end of the baseline period 
and after 2 and 4 weeks of intervention. A total of 62 subjects completed the study. No significant 
changes in frequency of defecations (1.41 ± 0.12 vs 1.28 ± 0.11 defecations/day), consistency score 
(2.45 ± 0.12 vs 2.52 ± 0.12) and stool dry mass (26.82 ± 2.38 vs 24.65 ± 0.63 g/day) between the 
group consuming scFOS from sucrose (n = 15, 10 females) and the control group consuming sucrose 
(n = 15, 8 females) were found at the end of the 4-week intervention period. The Panel considers 
that this study does not show an effect of scFOS from sucrose consumed at doses of 5.7 g/day for 
4 weeks on defecation frequency, consistency of stools or dry faecal mass. 
In a randomised, double-blind, placebo-controlled parallel study, Benamouzig (2015, unpublished 
study report) investigated the effect of scFOS from sucrose (Actilight® 4.6 g/day) vs placebo 
(maltodextrin) on the change in the frequency of defecations per week throughout a 6-week 
intervention period in adult subjects meeting Rome III criteria for functional constipation (n = 150, 
mean age 32.8 years, 119 females). The secondary outcomes included changes in stool consistency, 
gastrointestinal discomfort, total and segmental colonic transit time, and changes in microbiota in 
faecal samples. The sample size was calculated assuming a 30% difference in the weekly number of 
bowel movements between groups (n = 128 subjects). A total 150 of subjects were recruited to 
increase the power from 79.6% to 86.7%. The study consisted of three consecutive periods: 1-week 
run-in period, 6-week intervention period and 2-week follow-up period. The frequency of defecations 
was assessed by using a daily questionnaire which also included questions related to stool consistency 
(Bristol scale), and type and intensity of gastrointestinal symptoms (vomiting, nausea, bloating, 
borborygmus, flatulence, abdominal pain and diarrhoea). Three questionnaires were filled out by the 
participants in the run-in period and at the end of the intervention: the hospital anxiety and 
depression scale (HADS), the functional digestive disorders quality of life (FDDQOL), and a 3-day 24-
hour record of food intake. Total and segmental colonic transit time was measured by using radio-
opaque markers technique. Changes in faecal microbiota and changes of SCFA content were assessed 
in stool samples collected before and at the end of the intervention for 50% of the subjects. 
The per-protocol (PP) population consisted of 128 subjects who completed the study (n = 60 in the 
treatment group and n = 68 in the placebo group). There were 15 drop-outs in the treatment group 
and 7 drop-outs in the placebo group, respectively. Upon a request from EFSA, the applicant specified 
that most drop-outs in the intervention group (n = 10) were related to inadequate compliance and 
that the higher drop-out rate could not be attributed to the appearance of adverse effects. The Panel 
notes that a higher number of drop-outs in the intervention group (15 vs 7) may be related to the 
treatment. 
The results of the study were presented as means and standard deviations (SDs) for the PP and 
intention-to-treat (ITT) populations. Regarding the weekly frequency of defecations, between-group 
differences at week 6 and between-group differences in changes between week 6 and run-in were 
assessed. 
The baseline number of defecations/week was not significantly different between the two groups: 
2.90 ± 1.56 and 3.10 ± 1.70 for the scFOS and placebo groups, respectively (p = 0.60). In the PP 
analysis, the number of defecations per week at week 6 was not significantly different between 
groups 5.24 ± 2.79 and 4.42 ± 2.26 for the scFOS and placebo groups, respectively; p = 0.06), 
whereas the increase in the weekly frequency of defecations form the run-in period to week 6 was 
significantly higher in the scFOS group (+2.37 ± 2.92) compared to the placebo group (+1.36 ± 2.36; 
p = 0.03) using the Mann–Whitney test for independent samples. No differences were observed 
between groups in the ITT analyses with respect to the weekly frequency of defecations, neither at 
week 6 (5.04 ± 2.7 in scFOS group and 4.49 ± 2.23 in placebo group) or as changes from the run-in 
period (+2.14 ± 2.8 for scFOS group and +1.39 ± 2.33 for placebo group; p=0.06) using the same 
statistical analyses. 
Upon a request by EFSA to comment about the reasons why only the last week of the intervention 
was used for the analysis of the results of the study, the applicant reported to have re-analysed the 
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data using a mixed effects linear model taking into account all intermediate weeks in the model. 
However, the applicant provided only the significance values for the PP and ITT populations. The 
Panel is, therefore, unable to evaluate the results of this analysis and to draw conclusions from it. 
No significant differences were found between groups at the end of the intervention with respect to 
the consistency of stools and the total colonic transit time in the ITT or the PP analysis. 
The Panel notes that, in this study, the number of drop-outs in the intervention group was higher than 
in the control group (15 vs 7, respectively) and that the reasons for dropping-out may have been 
related to the intervention. In this context, the information provided does not ensure that the PP 
group is a random sample of the ITT group, and, therefore, the results for the PP group may be at 
high risk of bias. The Panel also notes that no effect of scFOS from sucrose on the weekly frequency 
of defecations, stool consistency or total colonic transit time has been reported for the ITT population. 
The Panel considers that no conclusions can be drawn from this study for the scientific substantiation 
of the claim. 
The applicant also submitted two randomised, placebo-controlled, cross-over studies investigating the 
effect of scFOS from sucrose on stool mass and using sucrose as placebo. In the study by Tahiri et al. 
(2001), the effect of scFOS from sucrose (10 g/day for 5 weeks) was investigated in 11 
postmenopausal women (mean age 59 years). The washout period was 3 weeks and stool mass was a 
secondary outcome. Wet stool mass (119.1 ± 39.1 vs 83.6 ± 28.0 g/day, p < 0.05) and dry stool 
mass (24.1 ± 5.3 vs 18.5 ± 4.4 g/day, p < 0.05) were significantly higher in the scFOS group 
compared to the placebo group. In contrast, in the study by Bouhnik et al. (1996) conducted in 
healthy volunteers (n = 20), the consumption of scFOS from sucrose (12.5 g/day for 12 days, with a 
12-day washout period) had no significant effect on wet stool weight compared to sucrose. The Panel 
notes that the dose of scFOS from sucrose used in these studies is more than double the dose 
proposed by the applicant in the conditions of use, and that other outcomes which could provide 
information about the maintenance of normal defecation (e.g. stool frequency, stool consistency, 
sensation of complete/incomplete evacuation, transit time) were not assessed in these two studies. 
The Panel notes that, in these studies, 10 g/day of scFOS consumed for 5 weeks had an effect on 
faecal bulk, whereas higher amounts (12.5 g/day) consumed for shorter periods of time (12 days) did 
not. 
Animal efficacy studies 
A significant increase in faecal bulk was observed in eight studies (Tokunaga et al., 1986; Younes et 
al., 1995; Sakaguchi et al., 1998; Le Blay et al., 2003; Tamura et al., 2006; Tanabe et al., 2006; Pan 
et al., 2009; Kaji et al., 2011) in rodents in which scFOS was 5% to 20% w/w of the feed, but not in 
one study in dogs in which scFOS in the feed was 1% w/w (Swanson et al., 2002b). 
The effect on intestinal transit time was evaluated in two studies in rats. Transit time was reduced 
after scFOS consumption in one study (Tokunaga et al., 1986) but not in the other study (Sakaguchi 
et al., 1998). 
The Panel notes that these studies provide evidence for an effect of high doses of scFOS from sucrose 
on faecal bulk in rodents. 
Mechanisms by which the food constituent could exert the claimed effect 
According to the applicant, there are several mechanisms by which the intake of scFOS could maintain 
normal bowel function. The applicant claims that scFOS from sucrose increase bacterial cell mass in 
the colon which, in turn, leads to an increase in faecal bulk. The applicant also claims that scFOS are 
only slightly absorbed in the small intestine (around 4%) and most reach the large intestine where 
they are completely fermented (Molis et al., 1996), and that SCFA produced from the fermentation of 
scFOS, together with the changes induced in the composition of the microbiota and in the composition 
of bile acids, can modulate intestinal motility in humans. 
In several human and animal studies, the consumption of scFOS increased the faecal concentration of 
Bifidobacteria, Lactobacilli and Clostridium coccoides (Hidaka et al., 1986; Stone-Dorshow and Levitt, 
1987; Hosoya et al., 1988; Tokunaga et al., 1993; Bouhnik et al. 1996; Molis et al., 1996; Bouhnik et 
al., 1999; Le Blay et al., 2003; Bouhnik et al., 2004; Boutron-Ruault et al., 2005; Bouhnik et al., 2006; 
Tamura et al., 2006; Bouhnik et al., 2007; Pan et al., 2009; Respondek et al., 2013). Other studies 
Short-chain FOS from sucrose and normal defecation 
 
 
 
www.efsa.europa.eu/efsajournal 10 EFSA Journal 2016;14(1):4366 
 
 
showed that consumption of scFOS increase SCFA excretion (Hosoya et al., 1988; Tokunaga et al., 
1993; Younes et al., 1995; Le Blay et al., 2003; Tsukahara et al., 2003; Bouhnik et al., 2004; Boutron-
Ruault et al., 2005; Tamura et al., 2006; Tanabe et al., 2006; Pan et al., 2009). An increase in 
Bifidobacteria and SCFA production has also been observed in in vitro studies where the faecal flora 
was incubated with scFOS (Luo et al., 1996; Probert  and Gibson, 2002; Saulmier et al., 2008; Stewart 
et al., 2008; Hernot et al., 2009; Likotrafiti et al., 2014). In one study, changes in the composition of 
bile acids in the large intestine after consumption of scFOS were shown (Boutron-Ruault et al., 2005). 
The Panel notes that in another study this effect on bile acids was not found (Bouhnik et al., 2007). 
The Panel considers that the above-mentioned studies provided some evidence that scFOS are 
fermented in the colon by the gut microbiota generating SCFAs, which may increase bacterial mass 
and thus faecal mass. The Panel considers, however, that the studies provided do not demonstrate 
that the magnitude of those changes induced by scFOS lead to significant changes in the frequency of 
defecations. 
Weighing of the evidence 
In weighing the evidence, the Panel took into account that one human intervention study from which 
conclusions could be drawn did not show an effect of scFOS from sucrose consumed at a dose of 
5.7 g/day for 4 weeks on defecation frequency, consistency of stools or dry faecal mass, and that in 
two other human intervention studies 10 g/day of scFOS consumed for 5 weeks increased faecal bulk, 
whereas higher amounts (12.5 g/day) consumed for shorter period of time (12 days) did not. The 
Panel also took into account that, although a number of animal efficacy studies and mechanistic 
studies provided some evidence that scFOS are fermented in the colon by the gut microbiota and 
increase bacterial mass and faecal bulk, the information provided by those studies does not 
demonstrate that the changes in SCFA or bile acids which may be induced by scFOS lead to significant 
changes in the frequency of stools. 
The Panel concludes that a cause and effect relationship has not been established between the 
consumption of scFOS from sucrose and maintenance of normal defecation under the proposed 
conditions of use. 
4. Conclusions 
On the basis of the data presented, the Panel concludes that: 
 The food constituent, scFOS from sucrose, which is the subject of the health claim, is 
sufficiently characterised. 
 The claimed effect proposed by the applicant is ‘maintaining normal intestinal transit 
regularity by increasing stool frequency’. The target population proposed by the applicant is 
the general population. Maintenance of normal defecation is a beneficial physiological effect. 
 A cause and effect relationship has not been established between the consumption of scFOS 
from sucrose and maintenance of normal defecation under the proposed conditions of use. 
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Documentation provided to EFSA 
1. Health claim application on short-chain fructooligosaccharides from sucrose and maintain 
normal intestinal regularity pursuant to Article 13(5) of Regulation (EC) No 1924/2006 (Claim 
serial No: 0436_FR). Submitted by Beghin Meiji, ZI et portuaire 67390 Marckolsheim, France 
and Tereos Syral, ZI et portuaire 67390 Marckolsheim, France. 
2. This application was received by EFSA on 12/6/2015. 
3. The scope of the application was proposed to fall under a health claim based on newly 
developed scientific evidence. The application included a request for the protection of 
proprietary data. 
4. The scientific evaluation procedure started on 24/7/2015. 
5. On 7/10/2015, the Working Group on Claims of the NDA Panel agreed on a list of questions for 
the applicant to provide additional information to accompany the application. The scientific 
evaluation was suspended on 15/10/2015 and was restarted on 30/10/2015, in compliance with 
Article 18(3) of Regulation (EC) No 1924/2006. 
6. On 29/10/2015, EFSA received the applicant’s reply. 
7. During its meeting on 11/12/2015, the NDA Panel, having evaluated the data, adopted an 
opinion on the scientific substantiation of a health claim related to scFOS from sucrose and 
maintenance of normal defecation. 
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Abbreviations 
DPav average degree of polymerization 
DM dry matter 
FDDQOL functional digestive disorders quality of life 
FOS fructooligosaccharides 
GF2 glucose–fructose–fructose (kestose) 
GF3 glucose–fructose–fructose–fructose (nystose) 
GF4 glucose–fructose–fructose–fructose–fructose (1F-β-fructofuranosyl nystose) 
HADS hospital anxiety and depression scale 
ITT intention-to-treat 
PP per-protocol 
SCFA short-chain fatty acids 
SD standard deviation 
scFOS short-chain fructooligosaccharides 
 
